A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://www.nature.com/articles/s41598-017-11764-2.pdf
Reference60 articles.
1. Dantas, A. N., de Morais, E. F., Macedo, R. A., Tinoco, J. M. & Morais Mde, L. Clinicopathological characteristics and perineural invasion in adenoid cystic carcinoma: a systematic review. Brazilian journal of otorhinolaryngology 81, 329–335, doi: https://doi.org/10.1016/j.bjorl.2014.07.016 (2015).
2. Hu, M. M., Hu, Y., He, J. B. & Li, B. L. Primary adenoid cystic carcinoma of the lung: Clinicopathological features, treatment and results. Oncology letters 9, 1475–1481, doi: https://doi.org/10.3892/ol.2015.2859 (2015).
3. Dillon, P. M., Chakraborty, S., Moskaluk, C. A., Joshi, P. J. & Thomas, C. Y. Adenoid Cystic Carcinoma: A Review of Recent Advances, Molecular Targets and Clinical Trials. Head & neck. doi: https://doi.org/10.1002/hed.23925 (2014).
4. Moskaluk, C. A. et al. Development and characterization of xenograft model systems for adenoid cystic carcinoma. Laboratory investigation; a journal of technical methods and pathology 91, 1480–1490, doi: https://doi.org/10.1038/labinvest.2011.105 (2011).
5. Pearson, A. T. et al. Patient-derived xenograft (PDX) tumors increase growth rate with time. Oncotarget. doi: https://doi.org/10.18632/oncotarget.6919 (2016).
Cited by 40 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Unique Cohorts of Salivary Gland Cancer Cells as an in-vitro Model of Circulating Tumor Cells;Journal of Maxillofacial and Oral Surgery;2024-06-16
2. Emerging role of MYB transcription factors in cancer drug resistance;Cancer Drug Resistance;2024-04-30
3. Zebrafish live imaging: a strong weapon in anticancer drug discovery and development;Clinical and Translational Oncology;2024-03-21
4. The mitotic checkpoint kinase BUB1 is a direct and actionable target of MYB in adenoid cystic carcinoma;FEBS Letters;2023-12-27
5. Organoid cultures for cancer modeling;Cell Stem Cell;2023-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3